Can bottom-up synthetic biology generate advanced drug-delivery systems?

• Verfasst von: Lussier, Félix [VerfasserIn]
• Verfasst von: Staufer, Oskar [VerfasserIn]
• Verfasst von: Platzman, Ilia [VerfasserIn]
• Verfasst von: Spatz, Joachim P. [VerfasserIn]
• Titel: Can bottom-up synthetic biology generate advanced drug-delivery systems?
• Verf.angabe: Felix Lussier, Oskar Staufer, Ilia Platzman, and Joachim P. Spatz
• Jahr: 2021
• Umfang: 15 S.
• Teil: volume:39
• Teil: year:2021
• Teil: number:5
• Teil: pages:445-459
• Teil: extent:15
• Fussnoten: Online 7 September 2020 ; Gesehen am 09.06.2021
• Titel Quelle: Enthalten in: Trends in biotechnology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1983
• Jahr Quelle: 2021
• Band/Heft Quelle: 39(2021), 5, Seite 445-459
• ISSN Quelle: 1879-3096
• DOI: doi:10.1016/j.tibtech.2020.08.002
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: bottom-up synthetic biology
• Sach-SW: droplet-based microfluidics
• Sach-SW: drug delivery
• K10plus-PPN: 1760100447

Abstract

Creating a magic bullet that can selectively kill cancer cells while sparing nearby healthy cells remains one of the most ambitious objectives in pharmacology. Nanomedicine, which relies on the use of nanotechnologies to fight disease, was envisaged to fulfill this coveted goal. Despite substantial progress, the structural complexity of therapeutic vehicles impedes their broad clinical application. Novel modular manufacturing approaches for engineering programmable drug carriers may be able to overcome some fundamental limitations of nanomedicine. We discuss how bottom-up synthetic biology principles, empowered by microfluidics, can palliate current drug carrier assembly limitations, and we demonstrate how such a magic bullet could be engineered from the bottom up to ultimately improve clinical outcomes for patients.